
Anixa Biosciences ANIX
$ 2.89
1.76%
Quarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Gross Profit 2011-2026 | ANIX
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 83.8 K | 344 K | 258 K | 82.6 K | 5.61 M | 1.68 M | 72.2 K | 943 K | 969 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.61 M | 72.2 K | 1.12 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Bioventus
BVS
|
388 M | $ 8.99 | 1.35 % | $ 599 M | ||
|
Brainsway Ltd.
BWAY
|
30.6 M | $ 13.73 | 0.59 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 25.9 | 0.27 % | $ 719 M | ||
|
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
2.8 B | $ 67.32 | 1.48 % | $ 26.3 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
Guardant Health
GH
|
144 M | $ 88.75 | 1.8 % | $ 11.1 B | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 153.71 | 1.14 % | $ 7.62 B | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 17.6 | 1.62 % | $ 938 M | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.26 B | $ 103.94 | 0.09 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 15.43 | 3.21 % | $ 467 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
18.5 M | $ 16.59 | -4.05 % | $ 2.15 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 100.49 | 2.95 % | $ 8.29 B | ||
|
IQVIA Holdings
IQV
|
3.79 B | $ 168.43 | 2.15 % | $ 29 B | ||
|
Danaher Corporation
DHR
|
14.5 B | $ 195.21 | 2.0 % | $ 139 B | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
Pacific Biosciences of California
PACB
|
45.8 M | $ 1.38 | 1.47 % | $ 414 M | ||
|
Illumina
ILMN
|
2.86 B | $ 120.84 | 1.31 % | $ 19.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 198.61 | -0.17 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
967 M | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
2.84 B | $ 112.75 | 0.82 % | $ 34.3 B | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.13 | 1.8 % | $ 1.44 M | ||
|
DarioHealth Corp.
DRIO
|
5.98 M | $ 8.75 | 3.92 % | $ 248 M | ||
|
NeoGenomics
NEO
|
314 M | $ 8.27 | 0.36 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
421 M | $ 9.27 | 1.76 % | $ 2.01 B | ||
|
Lantheus Holdings
LNTH
|
942 M | $ 80.45 | 2.48 % | $ 5.43 B | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
2.63 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
246 M | $ 455.15 | 0.33 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
2.39 B | $ 1 206.72 | 0.63 % | $ 24.9 B | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
81.5 M | $ 17.73 | 1.9 % | $ 397 M | ||
|
Twist Bioscience Corporation
TWST
|
6.96 M | $ 47.28 | 5.04 % | $ 2.83 B | ||
|
Invitae Corporation
NVTA
|
98.7 M | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
127 M | $ 198.38 | 0.35 % | $ 19.5 B |